Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.35 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.35 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.35 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
| ▸ | BAD | Q92934 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4614322 | 0.97 | CES2 (0.42) | CES2CES1CA1CA2ORAI1 | |
| SCHEMBL161234 | 0.95 | CES2 (0.40) | CES2CES1CA1CA2ORAI1 | |
| SCHEMBL11323370 | 0.95 | CES2 (0.40) | CES2CES1CA1CA2ORAI1 | |
| SCHEMBL9153089 | 0.83 | CA1 (0.36) | CA1CA2ALDH1A1 | |
| SCHEMBL3162019 | 0.83 | HSD11B1 (0.48) | PTGS1HSD11B1 | |
| SCHEMBL11859127 | 0.80 | CA1 (0.33) | CA1CA2 | |
| SCHEMBL8334157 | 0.78 | MAPK14 (0.53) | PTGS1 | |
| SCHEMBL10606718 | 0.75 | ESR1 (0.35) | — | |
| Ammonia Solution, Strong SCHEMBL19834103 | 0.74 | LMNA (0.42) | CES2CES1CA1CA2ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL3151956 | 0.74 | ALDH1A1 (0.48) | CES2CES1CA2ORAI1ORAI2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506170-B1 | METHOD FOR PRODUCING BICALUTAMIDE | HELM AG (DE) | 2008-02-27 | — | — | EP | disclosed |
| US-7323584-B2 | Process for preparing N-(4′-cyano-3′-trifluoromethylphenyl)-3-(4″-fluorophenylsulfonyl)-2-hydroxy-2-methylpropionamide | HELM AG (DE) | 2008-01-29 | — | — | US | disclosed |
| US-20050033082-A1 | Method for producing bicalutamide | CF PHARMA GYOGYSZERGYARTO KFT. (HU) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050033082-A1 | Method for producing bicalutamide | BRDT, NPEPPS, TET3 | CES2 175/4885CES1 1507/4885CA1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.